Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database.
作者信息
Naqash Abdul Rafeh, Stroud Chipman Robert Geoffrey, Butt Muhammad Umer, Dy Grace K, Hegde Aparna, Muzaffar Mahvish, Yang Li V, Hafiz Maida, Cherry Cynthia R, Walker Paul R
机构信息
a Division of Hematology/Oncology , East Carolina University , Greenville , NC , USA.
b Division of Cardiovascular Research, University of Kentucky Medical Center , Lexington , KY , USA.
出版信息
Acta Oncol. 2018 Jun;57(6):867-872. doi: 10.1080/0284186X.2017.1415460. Epub 2017 Dec 15.
Abstract
摘要
相似文献
1
Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database.
Acta Oncol. 2018 Jun;57(6):867-872. doi: 10.1080/0284186X.2017.1415460. Epub 2017 Dec 15.
2
Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Trials. 2019 Dec 19;20(1):753. doi: 10.1186/s13063-019-3951-x.
3
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Lung Cancer. 2017 Sep;111:176-181. doi: 10.1016/j.lungcan.2017.07.024. Epub 2017 Jul 24.
4
Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
Cancer Treat Rev. 2020 Apr;85:101979. doi: 10.1016/j.ctrv.2020.101979. Epub 2020 Feb 4.
5
Blood Predictive Biomarkers for Patients With Non-small-cell Lung Cancer Associated With Clinical Response to Nivolumab.
Clin Lung Cancer. 2020 Jan;21(1):75-85. doi: 10.1016/j.cllc.2019.08.006. Epub 2019 Aug 30.
6
Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers.
PLoS One. 2019 Jul 17;14(7):e0219060. doi: 10.1371/journal.pone.0219060. eCollection 2019.
7
Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
Cancer Med. 2019 Sep;8(11):5183-5193. doi: 10.1002/cam4.2411. Epub 2019 Jul 29.
8
KEYNOTE-024: Unlocking a pathway to lung cancer cure?
J Thorac Cardiovasc Surg. 2018 Apr;155(4):1777-1780. doi: 10.1016/j.jtcvs.2017.10.155. Epub 2017 Dec 23.
9
Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Lung Cancer. 2017 Oct;112:90-95. doi: 10.1016/j.lungcan.2017.07.034. Epub 2017 Aug 3.
10
There and back again: An immunotherapy tale.
J Thorac Cardiovasc Surg. 2018 Apr;155(4):1771-1774. doi: 10.1016/j.jtcvs.2017.11.102. Epub 2017 Dec 23.
引用本文的文献
1
Prognostic significance of the modified Glasgow Prognostic Score in NSCLC patients undergoing immune checkpoint inhibitor therapy: a meta-analysis.
Front Oncol. 2024 Oct 11;14:1449853. doi: 10.3389/fonc.2024.1449853. eCollection 2024.
2
The relationship between clinicopathological variables, systemic inflammation, and CT-derived body composition with survival in patients with advanced non-small cell lung cancer receiving nivolumab as a second-line treatment.
Cancer Med. 2023 Dec;12(24):22062-22070. doi: 10.1002/cam4.6805. Epub 2023 Dec 13.
3
Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer.
J Immunother Cancer. 2023 Oct;11(10). doi: 10.1136/jitc-2023-007310.
4
Investigation of response factors for monotherapy with immune checkpoint inhibitors in non-small cell lung cancer patients with PD-L1 expression <50.
Thorac Cancer. 2023 Sep;14(27):2754-2760. doi: 10.1111/1759-7714.15059. Epub 2023 Aug 3.
5
Association between baseline C‑reactive protein level and survival outcomes for cancer patients treated with immunotherapy: A meta‑analysis.
Exp Ther Med. 2023 Jun 8;26(2):361. doi: 10.3892/etm.2023.12060. eCollection 2023 Aug.
6
The prognostic and predictive roles of plasma C-reactive protein and PD-L1 in non-small cell lung cancer.
Cancer Med. 2023 Aug;12(15):16087-16097. doi: 10.1002/cam4.6262. Epub 2023 Jun 16.
7
Pre-treatment comorbidities, C-reactive protein and eosinophil count, and immune-related adverse events as predictors of survival with checkpoint inhibition for multiple tumour entities.
Cancer Med. 2023 Jun;12(11):12253-12262. doi: 10.1002/cam4.5919. Epub 2023 Apr 21.
8
Development of a Novel Predictive-Prognostic Scoring Index for Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer.
Cureus. 2023 Jan 1;15(1):e33234. doi: 10.7759/cureus.33234. eCollection 2023 Jan.
9
Case Report: Peripheral blood T cells and inflammatory molecules in lung cancer patients with immune checkpoint inhibitor-induced thyroid dysfunction: Case studies and literature review.
Front Oncol. 2022 Dec 7;12:1023545. doi: 10.3389/fonc.2022.1023545. eCollection 2022.
10
Biological Rationale for Peripheral Blood Cell-Derived Inflammatory Indices and Related Prognostic Scores in Patients with Advanced Non-Small-Cell Lung Cancer.
Curr Oncol Rep. 2022 Dec;24(12):1851-1862. doi: 10.1007/s11912-022-01335-8. Epub 2022 Oct 18.
本文引用的文献
1
Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis.
JCO Precis Oncol. 2017 Nov;1:1-15. doi: 10.1200/PO.16.00030.
2
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Lung Cancer. 2017 Sep;111:176-181. doi: 10.1016/j.lungcan.2017.07.024. Epub 2017 Jul 24.
3
Biomarkers of response to PD-1/PD-L1 inhibition.
Crit Rev Oncol Hematol. 2017 Aug;116:116-124. doi: 10.1016/j.critrevonc.2017.06.001. Epub 2017 Jun 9.
4
Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies.
Cancer Treat Rev. 2017 Jul;58:1-13. doi: 10.1016/j.ctrv.2017.05.005. Epub 2017 May 29.
5
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
Lung Cancer. 2017 Apr;106:1-7. doi: 10.1016/j.lungcan.2017.01.013. Epub 2017 Jan 25.
6
Immune-based Therapies for Non-small Cell Lung Cancer.
Anticancer Res. 2017 Feb;37(2):377-387. doi: 10.21873/anticanres.11330.
7
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
J Immunother Cancer. 2016 Aug 16;4:48. doi: 10.1186/s40425-016-0153-x. eCollection 2016.
8
Neutrophils in cancer: neutral no more.
Nat Rev Cancer. 2016 Jul;16(7):431-46. doi: 10.1038/nrc.2016.52. Epub 2016 Jun 10.
9
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.
Sci Transl Med. 2016 Mar 2;8(328):328rv4. doi: 10.1126/scitranslmed.aad7118.
10
Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Eur J Cancer. 2016 Feb;54:139-148. doi: 10.1016/j.ejca.2015.11.016. Epub 2016 Jan 5.
Zotero 插件